NCT05990959View on ClinicalTrials.gov

Risk Factors, Prognosis, and Potential Chemoprevention Drugs in Patients With Recurrent Hepatocellular Carcinoma After Curative Surgeries: a Nationwide Retrospective Cohort Study and a Multi-center Prospective Cohort Analysis

RecruitingOBSERVATIONAL

Enrollment

800

Participants

Timeline

Start Date

April 22, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Hepatocellular Carcinoma RecurrentSurgery

Interventions

OTHER

No intervention for research purpose

No any intervention will be applied under research purpose. All procedure or drugs would be given to the patient under best clinical judgment, not for research purpose.

Trial Locations (1)

404

RECRUITING

China Medical University Hospital, Department of Surgery, Taichung

All Listed Sponsors

collaborator

Ministry of Health and Welfare, Taiwan

OTHER_GOV

lead

China Medical University Hospital

OTHER